tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: Danaher (DHR), IQVIA Holdings (IQV)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Danaher (DHRResearch Report), IQVIA Holdings (IQVResearch Report) and Verve Therapeutics (VERVResearch Report) with bullish sentiments.

Danaher (DHR)

In a report released yesterday, Brandon Couillard from Jefferies reiterated a Buy rating on Danaher, with a price target of $310.00. The company’s shares closed last Thursday at $279.23.

According to TipRanks.com, Couillard is a top 25 analyst with an average return of 23.7% and a 71.0% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Nautilus Biotechnolgy, Bio-Rad Laboratories, and Mesa Laboratories.

Danaher has an analyst consensus of Strong Buy, with a price target consensus of $314.20, which is a 12.5% upside from current levels. In a report issued on July 13, Barclays also maintained a Buy rating on the stock with a $290.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

IQVIA Holdings (IQV)

In a report released yesterday, David Windley from Jefferies maintained a Buy rating on IQVIA Holdings, with a price target of $261.00. The company’s shares closed last Thursday at $225.63.

According to TipRanks.com, Windley is a top 100 analyst with an average return of 15.2% and a 69.7% success rate. Windley covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Molina Healthcare, and Stevanato Group.

Currently, the analyst consensus on IQVIA Holdings is a Strong Buy with an average price target of $262.13, representing a 16.2% upside. In a report issued on July 15, SVB Securities also initiated coverage with a Buy rating on the stock with a $256.00 price target.

Verve Therapeutics (VERV)

In a report released yesterday, Eun Yang from Jefferies maintained a Buy rating on Verve Therapeutics, with a price target of $75.00. The company’s shares closed last Thursday at $32.81.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 4.4% and a 47.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, United Therapeutics, and Blueprint Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verve Therapeutics with a $65.67 average price target, representing a 100.2% upside. In a report issued on July 18, BMO Capital also assigned a Buy rating to the stock with a $62.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DHR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More